Mitochondrial and nuclear cross talk in cell death: parthanatos
- PMID: 19076445
- PMCID: PMC4454457
- DOI: 10.1196/annals.1427.014
Mitochondrial and nuclear cross talk in cell death: parthanatos
Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear protein best known to facilitate DNA base excision repair. Recent work has expanded the physiologic functions of PARP-1, and it is clear that the full range of biologic actions of this important protein are not yet fully understood. Regulation of the product of PARP-1, poly(ADP-ribose) (PAR), is a dynamic process with PAR glycohydrolase playing the major role in the degradation of the polymer. Under pathophysiologic situations overactivation of PARP-1 results in unregulated PAR synthesis and widespread neuronal cell death. Once thought to be necrotic cell death resulting from energy failure, we have found that PARP-1-dependent cell death is dependent on the generation of PAR, which triggers the nuclear translocation of apoptosis-inducing factor resulting in caspase-independent cell death. This form of cell death is distinct from apoptosis, necrosis, or autophagy and is termed parthanatos. PARP-1-dependent cell death has been implicated in tissues throughout the body and in diseases afflicting hundreds of millions worldwide, including stroke, Parkinson's disease, heart attack, diabetes, and ischemia reperfusion injury in numerous tissues. The breadth of indications for PARP-1 injury make parthanatos a clinically important form of cell death to understand and control.
Figures


Similar articles
-
Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.Br J Pharmacol. 2014 Apr;171(8):2000-16. doi: 10.1111/bph.12416. Br J Pharmacol. 2014. PMID: 24684389 Free PMC article. Review.
-
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.Curr Vasc Pharmacol. 2005 Jul;3(3):209-14. doi: 10.2174/1570161054368625. Curr Vasc Pharmacol. 2005. PMID: 16026317 Review.
-
Mediation of cell death by poly(ADP-ribose) polymerase-1.Pharmacol Res. 2005 Jul;52(1):5-14. doi: 10.1016/j.phrs.2005.02.011. Pharmacol Res. 2005. PMID: 15911329 Review.
-
Parthanatos, a messenger of death.Front Biosci (Landmark Ed). 2009 Jan 1;14(3):1116-28. doi: 10.2741/3297. Front Biosci (Landmark Ed). 2009. PMID: 19273119 Free PMC article. Review.
-
Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases.Int Rev Cell Mol Biol. 2020;353:1-29. doi: 10.1016/bs.ircmb.2019.12.009. Epub 2020 Jan 27. Int Rev Cell Mol Biol. 2020. PMID: 32381174 Review.
Cited by
-
Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease.Neurochem Res. 2012 Nov;37(11):2589-96. doi: 10.1007/s11064-012-0895-x. Epub 2012 Oct 18. Neurochem Res. 2012. PMID: 23076628 Review.
-
Identification through high-throughput screening of 4'-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos.Br J Pharmacol. 2013 Jul;169(6):1263-78. doi: 10.1111/bph.12201. Br J Pharmacol. 2013. PMID: 23550801 Free PMC article.
-
FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration.Cell Death Differ. 2016 Nov 1;23(11):1873-1885. doi: 10.1038/cdd.2016.99. Epub 2016 Sep 23. Cell Death Differ. 2016. PMID: 27662363 Free PMC article.
-
Role of PARP inhibitors in cancer biology and therapy.Curr Med Chem. 2012;19(23):3907-21. doi: 10.2174/092986712802002464. Curr Med Chem. 2012. PMID: 22788767 Free PMC article. Review.
-
Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease.Mol Neurobiol. 2012 Aug;46(1):78-84. doi: 10.1007/s12035-012-8258-9. Epub 2012 Mar 20. Mol Neurobiol. 2012. PMID: 22430645 Review.
References
-
- Smith S. The world according to PARP. Trends Biochem Sci. 2001;26:174–9. - PubMed
-
- Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci. 2004;25:259–64. - PubMed
-
- Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004;26:882–93. - PubMed
-
- Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54:375–429. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous